Understanding how mitochondrial DNA damage affects Parkinson's disease
Mechanisms of mitochondrial genome integrity in familial and idiopathic Parkinson's disease
This study is looking at how damage to the tiny energy factories in our cells, called mitochondria, might be linked to Parkinson's disease, and it hopes to find ways to help improve their health and function for people living with this condition.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Duke University NIH-funded |
| Lab location | 1 site (Durham, United States) |
| Project ID | NIH-10986060 on NIH RePORTER |
What this research studies
This research investigates the role of mitochondrial DNA damage in both familial and idiopathic Parkinson's disease (PD). It focuses on the mechanisms by which mutations in the LRRK2 gene lead to mitochondrial dysfunction, which is a common feature in PD. The study aims to explore how the ATM protein, which is involved in DNA damage repair, can be targeted to potentially improve mitochondrial health and cellular function in patients with PD. By examining the relationship between ATM activation and mitochondrial DNA repair, the research seeks to uncover new therapeutic strategies for managing PD.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with familial or idiopathic Parkinson's disease, particularly those with known LRRK2 mutations.
Not a fit: Patients with Parkinson's disease caused by factors unrelated to mitochondrial dysfunction or those without a genetic predisposition may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to novel treatments that not only alleviate symptoms of Parkinson's disease but also slow its progression by repairing mitochondrial DNA damage.
How similar studies have performed: Preliminary studies have shown promise in targeting the ATM pathway to address mitochondrial DNA damage in Parkinson's disease, suggesting that this approach may be effective.
Where this research is happening
Durham, United States
- Duke University — Durham, United States (Active)
Researchers
- Principal investigator: Sanders, Laurie H — Duke University
- Study coordinator: Sanders, Laurie H
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.